Navigation Links
Spain is leading the fight against rare anemias in Europe
Date:11/19/2010

Madrid, Friday November 19th, 2010. It is estimated that rare diseases -those whose frequency is under 5 cases / 10,000 people- affect about 6% of the European population. In the field of anemia, 1% of couples are at risk of having a newborn with a severe syndrome of hemoglobin. More than 330,000 children are born worldwide each year affected by one of these diseases, being the most common disorders sickle cell anemia and thalassemia syndromes. In Spain, the average risk of having a newborn with a rare or unusual anemia is being increased due to African immigration. However, Spain is working on that issue and is the fifth of the 27 member countries that has developed a Strategic plan for rare diseases. It has been emphasized by European Commission sources during the 3rd European Symposium organized by ENERCA at the Cosmocaixa Madrid.

ENERCA European project (European Network for Rare and Congenital Anaemia) is, to date, the European reference network for the study of rare anemias. Since its inception in 2002, this initiative has uncovered a gap in the field of these diseases. However, misinformation and lack of institutional commitment forces professionals and affected patients to work closely. In fact, this is the first time that health professionals and patients join efforts in Spain in the fight against rare anemias. During a press meeting, Dr. Joan Lluis Vives-Corrons, head of the Anemia Unit at the Hospital Clnic of Barcelona and director of ENERCA, Mr. Antonio Cerrato, president of ALHETA (Spanish Association for the Control of Hemoglobinopathies and thalassemias), Mr. Antoni Montserrat, European Commission representative for the study of rare diseases, and Dr. Patricia Aguilar-Martinez, member of the World Health Organization, discussed the current situation of these diseases, and the main demands to improve the quality of life of patients.

Due to the
'/>"/>

Contact: lex Argem
aargemi@clinic.ub.es
0034-932-275-700
IDIBAPS - Institut d'Investigacions Biomdiques August Pi i Sunyer
Source:Eurekalert

Page: 1 2

Related biology news :

1. The birds of Spain, in a digital ornithological encyclopedia
2. The first hyperspectral scanner in Spain
3. Universitat Autonoma de Barcelona researchers first to clone mice in Spain
4. Small rodents encourage the formation of scrubland in Spain
5. Perennial vegetation, an indicator of desertification in Spain
6. Study in Spain and Romania confirms radon as second leading cause of lung cancer
7. The largest bat in Europe inhabited northeastern Spain more than 10,000 years ago
8. Waste could generate up to 7 percent of electricity in Spain
9. A new fossil species found in Spain
10. Exotic plant takes over dunes of Southern Spain
11. Ozone levels tend to be above recommended levels at this time of year in South West Spain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/13/2015)... Jul. 13, 2015 NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce ... patent 62/188684 for BEHAVIORAL-DIRECTED AUTHENTIATION METHOD ... convenient and secure method to make payments.  With ... methods, introduced with its groundbreaking voice-direct payment patent ...
(Date:7/9/2015)... 2015 Research and ... the "Biometrics for Banking; Market & Technology ... to their offering. The adoption for ... growth and the forecast is that by 2020 ... companies involved in delivering biometric systems to the ...
(Date:7/9/2015)... Calif. , July 9, 2015 /PRNewswire/ ... leading developer of human interface solutions, today ... the industry,s first fully hardware encapsulated fingerprint ... secure authentication technology is literally off the ... and biometric matching within the fingerprint sensor ...
Breaking Biology News(10 mins):NXT-ID Patents Behavior-Directed Payments 2NXT-ID Patents Behavior-Directed Payments 3NXT-ID Patents Behavior-Directed Payments 4Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 2Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 3
... CORVALLIS, Ore. Most large, clinical trials of vitamin ... no value or even harmful, have a flawed methodology ... value of these micronutrients, a new analysis suggests. ... naturally available in the human diet the same way ...
... to sequence the DNA of plants and animals has ... of DNA poses difficulties for sequencing specimens in museum ... issues, a recent study of 31 target spider species ... both time and body size are significant factors in ...
... flagship and charismatic species, very attractive for the ... relevant sentinel of the marine realm. Their,presence and ... indicate the health of the place, whereas,their disappearance, ... or health could,reflect negative environmental changes, whether of ...
Cached Biology News:Most clinical studies on vitamins flawed by poor methodology 2Most clinical studies on vitamins flawed by poor methodology 3The value of museum collections for development of DNA barcode libraries 2DNA barcoding to monitor marine mammal genetic diversity 2
(Date:7/30/2015)... 2015 AACC welcomed thousands of medical ... Annual Meeting & Clinical Lab Expo in ... meeting showcased revolutionary advancements in clinical testing technology ... providers to diagnose patients quickly and accurately and ... As of Wednesday, July 29, more ...
(Date:7/30/2015)... Texas (PRWEB) , ... July 30, 2015 , ... The ... and in-depth study on the current state of the global Propanol market with a ... Sinopec, CNPC, BASF, Eastman, Dow, Carboclor, Mitsui Chemicals, Oxea, ISU Chemical, Sanofi, Royal Dutch ...
(Date:7/30/2015)... 2015   Aratana Therapeutics, Inc . (NASDAQ: ... on the licensing, development and commercialization of innovative ... its strategic partner VetStem Biopharma, Inc. has shared ... AT-016, an adipose-derived allogeneic stem cell product exclusively ... pain in dogs. The double-blinded, multi-site, ...
(Date:7/30/2015)... 2015 Ascendis Pharma A/S (Nasdaq: ... innovative TransCon technology to address significant unmet medical ... six-month Phase 2 study to evaluate the safety ... 53 treatment-naïve, pre-pubertal children with growth hormone deficiency, ... with the top-line results from our Phase 2 ...
Breaking Biology Technology:Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 2Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 3Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 4Global Propanol Market Technical Data and Manufacturing Analysis 2020 2Global Propanol Market Technical Data and Manufacturing Analysis 2020 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7
... COLUMBIA, Md., Aug. 11 BP and Martek Biosciences Corporation (Nasdaq: ... Development Agreement (JDA) to work on the production of microbial oils ... operational capabilities to advance the development of a step-change technology for ... Under the terms of the multi-year agreement, Martek and BP ...
... , QUEBEC CITY, Aug. 11 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. ... biopharmaceutical company focused on endocrinology and oncology, today reported financial and ... ended June 30, 2009. , , , ... - Two poster presentations at the American Association of Cancer, ...
... , SANTA MONICA, Calif. and LAS VEGAS, ... one of the largest umbilical cord blood stem cell preservation companies ... the life saving potential of stem cells to families nationwide and ... square foot facility in Las Vegas for conversion into a state-of-the-art ...
Cached Biology Technology:BP and Martek Biosciences Enter a Joint Development Agreement to Deliver Advanced Biodiesels 2BP and Martek Biosciences Enter a Joint Development Agreement to Deliver Advanced Biodiesels 3BP and Martek Biosciences Enter a Joint Development Agreement to Deliver Advanced Biodiesels 4AEterna Zentaris Reports Second Quarter 2009 Financial and Operating Results 2AEterna Zentaris Reports Second Quarter 2009 Financial and Operating Results 3AEterna Zentaris Reports Second Quarter 2009 Financial and Operating Results 4AEterna Zentaris Reports Second Quarter 2009 Financial and Operating Results 5AEterna Zentaris Reports Second Quarter 2009 Financial and Operating Results 6AEterna Zentaris Reports Second Quarter 2009 Financial and Operating Results 7AEterna Zentaris Reports Second Quarter 2009 Financial and Operating Results 8Cord Blood America New Las Vegas Stem Cell Laboratory Scheduled for Opening in 4th Quarter 2009 2Cord Blood America New Las Vegas Stem Cell Laboratory Scheduled for Opening in 4th Quarter 2009 3
... to rapidly and reliably amplify unknown ... APA Technology. APAgene provides hassle-free, ready-to ... price. All necessary ingredients are provided ... can be used for identifying transgene/genomic ...
Recommended for supporting the growth of anchorage-dependent cells including human and mouse stromal cells, mesenchymal cells and cell lines....
... number is a new product ... Cornings product number. If showing ... under the old Sigma-Aldrich number ... for assistance. ID clarifier: cap, ...
Extremely high efficiency packaging extracts useful for transfecting our EpiFOS™ or CopyControl™ Fosmids, or any DNA vector with cos sites. A tremendous value when conpared to the competition...
Biology Products: